All In Biotech

Drug Trial Radar · NCT02099110

Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)

A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin Compared With Ertugliflozin Alone and Sitagliptin Alone, in the Treatment of Subjects With T2DM With Inadequate Glycemic Control on Metformin Monotherapy

Last checked: Nov 20, 2026Latest source record: Sep 12, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,233 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,233

Actual

Start

Apr 22, 2014

Primary completion

May 26, 2016

Study completion May 26, 2016

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
Pfizer
First posted
Mar 28, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study of co-administration of ertugliflozin (MK-8835/PF-04971729) and sitagliptin given together or alone along with metformin in participants with Type 2 diabetes mellitus (T2DM) and inadequate glycemic control on metformin monotherapy. The primary hypothesis of this study is that ertugliflozin 15 mg daily plus sitagliptin 100 mg daily provides greater hemoglobin A1C (A1C)-lowering compared with sitagliptin 100 mg daily alone.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • Matching Placebo to Ertugliflozin 5 mgDrug

    Placebo to ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period

  • Matching Placebo to Ertugliflozin 10 mgDrug

    Placebo to ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period

  • Matching Placebo to sitagliptin 100 mgDrug

    Placebo to sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period

  • Ertugliflozin 5 mgDrug

    Ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period

  • Ertugliflozin 10 mgDrug

    Ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period

  • Sitagliptin 100 mgDrug

    Sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period

  • Metformin >= 1500 mg/dayDrug

    Metformin \>= 1500 mg/day, tablets, oral, for 52 weeks while receiving blinded investigational product during the double-blind treatment period

  • Insulin Glargine Rescue MedicationBiological

    Open-label insulin glargine, subcutaneous injection, as required as a rescue medication; dose determined per the investigator's discretion

  • Glimepiride Rescue MedicationDrug

    Open-label glimepiride tablets, oral, as required as a rescue medication, dose determined per the investigator's discretion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in A1C at Week 26: Excluding Rescue ApproachTime frame: Baseline and Week 26
  2. Percentage of Participants Who Experienced an Adverse Event (AE): Including Rescue ApproachTime frame: Up to 54 weeks
  3. Percentage of Participants Who Discontinued Study Treatment Due to an AE: Including Rescue ApproachTime frame: Up to 52 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.